Tumor angiogenesis is important in tumorigenesis and therapeutic interventions in cancer. To know inhibitor and effector of tumor angiogenesis in cancer, the specific gene of tumor and angiogenesis may develop the mechanisms of cancer suppression and therapy. Recently, we described the role of RalA-binding protein 1 (RLIP76) in tumor angiogenesis. Tumor vascular volumes were diminished, and vessels were fewer in number, shorter, and narrower in RLIP76 knockout mice than in wild-type mice. Moreover, angiogenesis in basement membrane matrix plugs was blunted in the knockout mice in the absence of tumor cells, with endothelial cells isolated from the lungs of these animals exhibiting defects in migration, proliferation, and cord formation in vitro. RLIP76 is expressed in most human tissues and is overexpressed in many tumor types. In addition, the protein regulates tumorigenesis and angiogenesis in vivo and in vitro. As the export of chemotherapy agents is a prominent cellular function of RLIP76, it is a major factor in mechanisms of drug resistance. Moreover, RLIP76 acts as a selective effector of the small GTPase, R-Ras, and regulates R-Ras signaling, leading to cell spreading and migration. Furthermore, in skin carcinogenesis, RLIP76 knockout mice are resistant, with tumors that form showing diminished angiogenesis. Thus, RLIP76 is required for efficient endothelial cell function and angiogenesis in solid tumors. Introduction RalA-binding protein 1 (RLIP76) plays an important role in cancer, such as melanoma regression, regression of lung and colon cancer, colorectal cancer, breast cancer, and carcinoma cancer [21, 24, 32, 35, 36] . RLIP76 knockout mice are highly resistant to chemical carcinogenesis and are even resistant to the growth of subcutaneously implanted cancer cells [20, 21, 32, 33, 36, 37, 41] . Recently, we have been published in RLIP76 regulates tumor angiogenesis in vivo and in vitro, these studies suggest that suppression of RLIP76 can inhibit vascular growth and/or angiogenesis for tumor angiogenesis.
Introduction
RalA-binding protein 1 (RLIP76) plays an important role in cancer, such as melanoma regression, regression of lung and colon cancer, colorectal cancer, breast cancer, and carcinoma cancer [21, 24, 32, 35, 36] . RLIP76 knockout mice are highly resistant to chemical carcinogenesis and are even resistant to the growth of subcutaneously implanted cancer cells [20, 21, 32, 33, 36, 37, 41] . Recently, we have been published in RLIP76 regulates tumor angiogenesis in vivo and in vitro, these studies suggest that suppression of RLIP76 can inhibit vascular growth and/or angiogenesis for tumor angiogenesis.
Tumor angiogenesis is important for tumor growth and therapeutic intervention in cancer. These primarily consist of the release of angiogenic factors, activation of metalloproteases to break down extracellular matrix, and subsequent remodeling. Also angiogenic stimulants induced in tumor cells and produced, and endothelial cells are responded in proliferation, migration, spreading, and angiogenesis to tumor. To know inhibitor and/or its effector of tumor angiogenesis in cancer, the specific gene of tumor and angiogenesis may develop the mechanisms of cancer suppression and therapy. This review will focus on the function and role of RLIP76 in tumor angiogenesis and cancer.
Functions of RLIP76
RLIP76 is a modular, multifunctional protein of 655 amino acids, harboring an N-terminal putative helical domain of poorly characterized function, a central RhoGAP domain, and a conserved Ral-binding domain (RalBD) near the C-terminus (Fig. 1) . Like all Ras superfamily small G proteins, Ral proteins are signal transducers that become activated upon release of guanine diphosphate (GDP) and binding to guanine triphosphate (GTP), upon which Ral undergoes a conformational shift to expose high affinity binding sites for signaling effectors. Thus RLIP76 is a unique Ral effector, connecting upstream activation of Ral to downstream molecular and cellular events.
Also the Ral effector property of RLIP76 was described as linking Ral to Rho GTPase pathways through the -Review - RhoGAP domain [9, 17, 44] . The Rho subfamily of Ras small G proteins, most prominently RhoA, Rac and Cdc42, are, like Ras and Ral, regulated by guanine nucleotide exchange, such that RhoGAPs facilitate conversion from the GTPbound, active state to the GDP-bound, inactive state. Thus, an important cellular and physiological function of RLIP76 is to couple Ral effector function with Rho signaling and actin cytoskeletal remodeling, promoting altered cell morphologies.
Moreover, our group identified RLIP76 as a selective effector of the small GTPase R-Ras, and found that RLIP76 regulates R-Ras signaling leading to cell spreading and migration [8, 11] . These effects are the result of RLIP76 adapter function, whereby it recruits ARNO, a small GTPase guanine exchange factor, to R-Ras at recycling endosomes to regulate vesicular trafficking necessary for spreading and migration [8] . RLIP76 also potentiates Ral-mediated cell spreading, potentially through similar signaling pathways [7] . Thus, RLIP76 regulates a broad spectrum of molecular, cellular and physiological processes, many of which stem from its function as a molecular adapter in various cellular locales (Fig. 2 ).
RLIP76 in cancer
RLIP76 is expressed in most human tissues including liver, heart, ovary, lung, muscle, and kidney as well as in most human tumor cell lines, and is over-expressed in multiple cancers, such as lung and ovarian carcinomas and melanomas [3, 4, 6, 28] . Since a prominent cellular function of RLIP76 is export of chemotherapy agents, it is a major factor in the mechanisms of drug resistance. Moreover, blockade of RLIP76 with targeting antibodies or antisense has been shown to greatly increase sensitivity to radiation and chemotherapy and lead to pronounced tumor regression in multiple types of solid tumors in mice, including xenografted tumors of cancer cells [32, 33, 36] .
Of the many functions of RLIP76 related to cancer initiation and progression, the most thoroughly characterized is as a molecular transporter of glutathione-electrophile conjugates (GS-E). GS-Es form by thioether conjugation of glutathione (GSH, between 1-10 mM cytolosic concentration in cells), an electron donor and thus a reducing agent, with electrophilic or oxidant chemicals that are derived both endogenously (endobiotics) and from the environment (xenobiotics). In this way, GSH acts as a scavenger for alkylating agents and other electrophiles [15] . GS-E conjugates become trapped in cells, and require energy-dependent transport for their removal to prevent toxicity both by excessive GS-E and by impairing the overall process of reduction of electrophilic toxins [16, 42] . Some of this transport function is carried out by ATP-binding cassette (ABC) transporters [1, 10] . Thus, in addition to removal from cells of toxic endobiotics such as 4-hydroxynonenal (4-HNE), GS-E transport is also essential for protection from xenobiotics [16, 43] . Multi-drug resistance (MDR), particularly for alkylating chemotherapeutic drugs, is very often the result of a failure of transport in the target cells; hence, transporters such as ABC type are classified as MDR proteins, which have long been pursued as therapeutic targets to inhibit drug resistance in cancer cells [19, 29] .
RLIP76 is a novel, non-ABC type transporter, which utilizes both of its two ATP binding sites -in the N-terminal domain (aa 69-74) and adjacent to the RalBD (418-425) -for ATPase and transport activity, but lacks the canonical Walker domain of ABC-type transporters [25] . Interestingly, PKC-mediated phosphorylation of RLIP76 increases its transport activity [27] . A wealth of subsequent studies showed that RLIP76 is the major transporter for a wide range of structurally distinct endobiotics and xenobiotic chemotherapy agents, including GS-E, doxorubicin, sulfates, leukotriene C4, vinorelbine, glucorinides, colchicine, and other organic anions and cations [2, 5, 27, 30, 34, 36, 38, 39] . Due to this broad spectrum of transport targets, RLIP76 plays important roles in resistance to apoptosis due to heat shock and oxidative stress (in part through interaction with HSF-1), radiation sensitivity, and perhaps most prominently, to multi-drug resistance in cancer therapy [22, 37, 40] .
RLIP76 regulates tumor angiogenesis RLIP76 has unique functions in endothelial cells, specialized squamous epithelia that form the inner core of all blood vessels, and are the sole cellular components of the microvasculature [14, 21] . We have recently found a role for RLIP76 in tumor angiogenesis (Fig. 3) . Angiogenesis, the outgrowth of new blood vessels from existing ones, is required for progression of tumor growth and metastasis. Solid tumors require a nutrient blood supply to grow beyond~1 mm diameter, and inhibiting tumor angiogenesis has long been pursued as an approach to preventing tumor growth and subsequent metastasis [23] . Angiogenesis is a complex process resulting from combined simultaneous up-regulation of proliferation and migration in endothelial cells. During initial stages of angiogenesis, proliferating and migrating endothelial cells convert to a spindle-shaped morphology and organize into branched capillary networks, which differentiate into fully-formed lumenal vessels carrying blood from the source vasculature to the new sites such as into solid tumors [23] .
Based on the ability of RLIP76 to interact with R-Rasa modulator of tumor angiogenesis -as well as with other proteins important for endothelial function, we recently investigated a potential physiological role for RLIP76 in angiogenesis in solid tumors xenografted in mice [18] . Tumor growth from B16F10 melanoma or Lewis lung carcinoma cells xenografted into the flanks of C57Bl/6 wild type (WT) mice was blunted in isogenic RLIP76 -/-mice. We used X-ray micro-computed tomography to reconstruct tumor vascular structures in 3D in resected tumors from WT and RLIP76 knock-out mice, and found defects in both the extent and form of tumor angiogenesis in RLIP76 knock-out mice. Specifically, tumor vascular volumes were diminished and vessels were fewer in number, shorter, and narrower in RLIP76 knock-out mice than in WT mice. Moreover, we found that angiogenesis in basement membrane matrix plugs was blunted in the knockout mice in the absence of tumor cells, with endothelial cells isolated from the lungs of these animals exhibiting defects in migration, proliferation and cord formation in vitro [14] . Furthermore, in a model of induced skin carcinogenesis, to which RLIP76 knock-out mice are already resistant [13] , the tumors that did form showed diminished angiogenesis; conversely, liposomemediated reconstitution of RLIP76 expression restored tumor growth and tumor angiogenesis in this model [14] . Thus, in addition to regulating tumor cell growth, RLIP76 is required for efficient endothelial cell function and angiogenesis in solid tumors.
Conclusions
In tumor angiogenesis, effects of RLIP76 targeting in tumor xenografts are the result of combinatorial effects in tumor cells and stromal cells. The prevention of xenografted tumor growth and synergy with inhibition of tumor angiogenesis in RLIP76 knockout mice, and conversely the enhanced tumor angiogenesis observed following ectopic application of RLIP76 in the knockout mice, strongly supports the idea of a one-two punch attack on growth of solid tumors, by blocking RLIP76 function in tumor cells and the tumor vasculature.
